Amicus Therapeutics, Inc. (FOLD) — SEC Filings
Amicus Therapeutics, Inc. (FOLD) — 46 SEC filings. Latest: EFFECT (Apr 30, 2026). Includes 15 8-K, 9 SC 13G/A, 7 POSASR.
View Amicus Therapeutics, Inc. on SEC EDGAR
Overview
Amicus Therapeutics, Inc. (FOLD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 30, 2026: Amicus Therapeutics, Inc. filed an EFFECT form on April 30, 2026, indicating the effectiveness of a filing related to their securities. The filing, with accession number 9999999995-26-001363, was accepted at 00:15:02. The effectiveness date for the filing was April 29, 2026.
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 42 neutral. The dominant filing sentiment for Amicus Therapeutics, Inc. is neutral.
Filing Type Overview
Amicus Therapeutics, Inc. (FOLD) has filed 3 EFFECT, 7 POSASR, 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of FOLD's 29 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $169.061M |
| Net Income | $17.306M |
| EPS | N/A |
| Debt-to-Equity | 2.77 |
| Cash Position | $190.553M |
| Operating Margin | 20.27% |
| Total Assets | $868.811M |
| Total Debt | $391.985M |
Key Executives
- Dr. Brad Smith
Industry Context
Amicus Therapeutics operates in the highly specialized and competitive biotechnology sector, focusing on rare genetic diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Key trends include advancements in gene therapy, personalized medicine, and strategic partnerships to expand pipelines and market reach, as evidenced by Amicus's licensing agreement for DMX-200.
Top Tags
sec-filing (8) · amendment (5) · financial-condition (5) · financial-reporting (4) · 10-Q (4) · pharmaceuticals (4) · shelf-registration (3) · Pharmaceuticals (3) · results-of-operations (3) · filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Effectiveness Date | 2026-04-29 | The date the filing officially became active. |
| Acceptance Date | 2026-04-30 | The date the SEC processed and accepted the filing. |
| File Number | 333-209822 | Associated with the registration statement |
| Document Size | 28300 | Size of the POSASR document in bytes. |
| Net product sales for Q3 2025 | $169.061M | Increased 19.46% from $141.517 million in Q3 2024 |
| Net income for Q3 2025 | $17.306M | Swung from a net loss of $6.729 million in Q3 2024 |
| Net loss for YTD Q3 2025 | $28.800M | Improved from a net loss of $70.845 million in YTD Q3 2024 |
| Cash and cash equivalents as of Sep 30, 2025 | $190.553M | Decreased from $213.752 million at Dec 31, 2024 |
| Total Assets as of Sep 30, 2025 | $868.811M | Increased from $785.033 million at Dec 31, 2024 |
| Accumulated deficit as of Sep 30, 2025 | $2.8B | Indicates historical losses despite recent quarterly profit |
| Shares outstanding as of Oct 24, 2025 | 308,533,548 | Reflects total common stock outstanding |
| Q2 2025 Net Loss | $70.5M | Increased from $55.2M in Q2 2024, indicating widening losses. |
| YTD 2025 Net Loss | $135.7M | Increased from $108.9M in YTD 2024, showing accelerated cash burn. |
| Accumulated Deficit | $2.1B | Increased from $1.9B at year-end 2024, reflecting ongoing operational losses. |
| Total Stockholders' Equity | $1.1B | Decreased from $1.2B at year-end 2024, indicating erosion of shareholder value. |
Forward-Looking Statements
- {"claim":"Amicus Therapeutics' stock price may see increased investor confidence due to this significant institutional stake.","entity":"AMICUS THERAPEUTICS, INC.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Amicus Therapeutics, Inc. (FOLD)?
Amicus Therapeutics, Inc. has 46 recent SEC filings from Jan 2024 to Apr 2026, including 15 8-K, 9 SC 13G/A, 7 POSASR. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of FOLD filings?
Across 46 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 42 neutral. The dominant sentiment is neutral.
Where can I find Amicus Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Amicus Therapeutics, Inc. (FOLD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Amicus Therapeutics, Inc.?
Key financial highlights from Amicus Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for FOLD?
The investment thesis for FOLD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Amicus Therapeutics, Inc.?
Key executives identified across Amicus Therapeutics, Inc.'s filings include Dr. Brad Smith.
What are the main risk factors for Amicus Therapeutics, Inc. stock?
Of FOLD's 29 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Amicus Therapeutics, Inc.?
Recent forward-looking statements from Amicus Therapeutics, Inc. include guidance on {"claim":"Amicus Therapeutics' stock price may see increased investor confidence due to this significant institutional s.